Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial
Intra-arterial tenecteplase administered after successful reperfusion by thrombectomy shows tolerable safety at low doses in large vessel occlusion stroke.
Dose escalation revealed unacceptable hemorrhagic risk at 0.1250 mg/kg, but doses 0.0313 mg/kg and 0.0625 mg/kg were safe for further study.
Preliminary efficacy signals suggest a trend toward improved 90-day functional independence but were not statistically significant in this early-phase trial.
Findings support progressing to larger randomized trials to clarify therapeutic benefit and optimize dosing strategies.
